Insmed Incorporated

Organisation

700 US Highway 202/206, Bridgewater, NJ, United States, 08807

Headquarters

1664

Employees

Health Technology

Industry

William Lewis

Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It also develops brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1(DPP1) that is in phase 3 clinical trial for the treatment of bronchiectasis; and in phase 2 clinical trial for the treatment of chronic rhinosinusitis without nasal polyps and hidradenitis suppurativa. In addition, the company is developing treprostinil palmitil inhalation powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil, which is in phase 3 clinical trial for the treatment of pulmonary hypertension associated with interstitial lung disease; and phase 2 clinical trial for the treatment of pulmonary arterial hypertension. Further, it develops INS1201, a microdystrophin adeno-associated virus gene replacement therapy which is in phase 1 clinical trial for the treatment of Duchenne muscular dystrophy, as well as it is also developing pre-clinical research programs for gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. In addition, it provides INS1148, monoclonal antibody targeting stem cell factor called SCF248 that is in phase-2 clinical trial for the treatment of interstitial lung disease, and asthma; and INS1202, an intrathecally delivered gene therapy which is in phase 1 of clinical trial for the treatment of amyotrophic lateral sclerosis.  The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.

Price

Target

Insmed Incorporated (INSM) Price vs Consensus Price Target

As per the chart shown above, analysts believe that the Insmed Incorporated (INSM) share price will touch around $215.58 in next 12-months.

Currently 23 wall-street analysts regularly analyze the financials of Insmed Incorporated on a frequent basis to provide recommendations along with target share price. 23 analysts offering 12-month price forecasts for Insmed Incorporated (INSM) have a share price target of $215.58. This median of share price forecast represents a 40.57% upside from the latest price of $153.36 as on 31.03.26.

Insmed Incorporated (INSM) Share Price Forecast

Home

US Stocks

Insmed Incorporated (INSM)

Insmed Incorporated Stock Forecast

Insmed Incorporated Stock Forecast & Price Target (Analyst Recommendation) | INDmoney

Percentage Difference

Insmed Incorporated (INSM): Difference between Current Price & Median Forecasted Price

Below is a chart showing the percentage difference between Insmed Incorporated's share price and its median forecast price. As on 31.03.26, the difference is -1.64%

Insmed Incorporated Forecast and Target Price

Insmed Incorporated (INSM) Share Price Forecast

Insmed Incorporated (INSM) Price vs Consensus Price Target

Insmed Incorporated (INSM) Share Price Forecast v/s Share Price Today

Insmed Incorporated (INSM): Difference between Current Price & Median Forecasted Price

Insmed Incorporated (INSM) Share Price Technical Analysis

50 Day Moving Average v/s Current Share Price

200 Day Moving Average v/s Current Share Price